Navigation Links
Cholesterol Drug Fails to Slow Progression of Coronary Disease,,Cleveland Clinic Study Reports

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- Cleveland Clinic researchers today report that the drug torcetrapib, despite raising high density lipoprotein cholesterol (HDL) or the "good" cholesterol by more than 60%, did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe.

Steven Nissen, M.D., Chairman of Cardiovascular Medicine at Cleveland Clinic and lead investigator of this clinical trial, will present the study on Monday, March 26 at 8:30 a.m. at the of Cardiology's (ACC) 56th Annual Scientific Session. Dr. Nissen is also President of the ACC. The study will be simultaneously published in the New England Journal of Medicine.

All development of this drug was terminated on Dec. 2, 2006 after the safety board monitoring a separate large clinical outcomes trial reported that torcetrapib increased the risk of death and other adverse cardiovascular outcomes.

"We found that the torcetrabip/atorvastatin combination markedly increased good cholesterol levels and lowered bad cholesterol in patients. Unfortunately this drug also substantially raised blood pressure and failed to slow the buildup of plaque," Dr. Nissen said. "It is yet to be determined of this failure represents a problem unique to torcetrapib or predicts a lack of efficacy for the entire class of similar drugs. These findings further demonstrate the great difficulty in developing therapies to disrupt the atherosclerotic disease process."

The development of drugs to raise HDL has been a key research priority because, despite lowering LDL (low-density lipoprotein, or "bad") cholesterol with statin drugs, many patients continue to experience heart attacks, stroke or sudden cardiac death.

A total of 1,188 coronary artery disease patients were enrolled in the "Investigation of Lipid Level management using coronary UltraSound To assess Reduction of Atherosclerosis by CET
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
4. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
5. CSL Therapy That Mimics “Good” Cholesterol May Reduce Plaque Volume in Coronary Arteries
6. CSL Therapy That Mimics Good Cholesterol May Reduce Plaque Volume in Coronary Arteries
7. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
8. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
9. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
Post Your Comments:
(Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
(Date:5/23/2013)... 2013 EarlySense, the market leader ... prize for ,Best Novel Idea, at the 8 th ... International Conference, hosted this year in the UK by ... clinical research team studying the impact of the EarlySense ... Los Angeles . The prize was awarded ...
(Date:5/23/2013)... 2013  Inhibikase Therapeutics, Inc., an emerging leader ... will present new results on its antiviral program ... by the PML Consortium (composed of Pfizer, Bristol-Meyers ... is the causative agent of Progressive Multifocal Leukoencephalopathy ... an extended release formulation, can clear JC polyomavirus ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 2Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 3Clinical Team Researching the Impact of the EarlySense System Wins 'Best Novel Idea' Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2
... Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity ... Mutations - (1,2)-The First Presentation of Data on BIBF ... Ingelheim will present new data on the company,s two ... the 2009 Annual Meeting of the American Society of ...
... TYRX, Inc., a leader in the ... the 30th Annual Scientific Sessions of the Heart ... its AIGISRX(TM) Antibacterial Envelope Retrospective Registry.AIGIS is an ... that help provide protection against infections associated with ...
Cached Medicine Technology:Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 2TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 3TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 4TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 5TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry 6
(Date:5/23/2013)... The Rottenstein Law Group LLP, a New York-based nationwide ... Information Center at http://www.rotlaw.com/tylenol , dedicated to issues ... considering filing lawsuits. , The painkiller Tylenol (acetaminophen) ... according to a 2009 report from the U.S. Food ... FDA warned consumers against using more than the recommended ...
(Date:5/23/2013)... Washington, DC (PRWEB) May 23, 2013 ... have a great deal of control over their level ... their weight, yet far fewer are actually taking that ... International Food Information Council (IFIC) Foundation’s 2013 Food & ... of respondents say it’s possible to have “a great ...
(Date:5/23/2013)... IL (PRWEB) May 23, 2013 Jeanne ... fifth anniversary of its popular and only free OCD ... a successful continuing resource for OCD sufferers, the group ... OCD, and related disorders. This allows group participants ... and Exposure and Response Prevention. , “Participants in Beyond ...
(Date:5/23/2013)... May 23 (HealthDay News) -- Schools should ensure ... physical activity each day to support their health ... new report. Although previous studies show ... promotes health and development, it,s estimated that only ... meeting this recommendation, according to the report from ...
(Date:5/23/2013)... Reporter , , THURSDAY, May 23 (HealthDay News) -- Heavy ... as methamphetamine or crack cocaine, a new study contends. ... or ,coke mouth, it is startling to see the ... same," said Dr. Mohamed Bassiouny, a professor of restorative ... Philadelphia. Methamphetamine, crack cocaine and soda -- sweetened ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:Beyond OCD Support Group Marks Fifth Anniversary 2Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3
... SHANGHAI, Sept. 10 /PRNewswire-Asia/ -- ... announced that Dr. Ge Li, the Company,s Chairman and ... Healthcare,Unplugged Conference in New York on Tuesday, September 15, ... present at the Bank of America Merrill,Lynch Global Healthcare ...
... 9 Family Research Council President Tony Perkins made the ... joint session of Congress. , , ... Tomorrow night in a live webcast at frcaction.org, ... Perkins will be joined by Senator Jim DeMint (R-SC), House ...
... , , MANASSAS, Va., Sept. 9 , ... of ConservativeHQ.com, regarding President Obama,s speech on health care legislation: ... far-left agenda by re-launching an effort for government-run health care. ... Obama is re-launching the conservative movement. , , ...
... , , , ... no meaningful health care reform , , ... Congress Wednesday evening, USAction President William McNary called on Congress to ... companies - and pass quality, affordable health care reform with a ...
... , OAKLAND, Calif., Sept. 9 ... "Technologies for Home and Community-Based Services: Considering the Options," at ... the City Center Marriott Hotel in Oakland on Friday, September 11, ... Lindeman, Ph.D.; Lynn Redington, Dr.PH., M.B.A.; and Valerie Steinmetz. They will ...
... action of nitrogen-containing bisphosphonate (N-BP) cancer drugs, used to ... bone metastasis, has been almost entirely unknown. Researchers writing ... have used ,barcoded, yeast mutants to identify new ... opening up opportunities for the development of new anticancer ...
Cached Medicine News:Health News:WuXi PharmaTech to Participate in Upcoming Investor Conferences 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2Health News:Richard Viguerie: Obamacare is Restarting the Conservative Movement 2Health News:Technologies That Redefine Care for Older Americans to be Focus of Conference Session Led by Center for Technology and Aging 2
... The G-4 goniolaser lens features 4 precisely ... 360° view of the anterior chamber angle ... design (flanged glass contact element) provides a ... segment. 4 mirror lens provides ...
The Mid Field 30° lens has a bi-concave design to provide a wider field of view with a 30 degree offset image....
... The Chalam 45° Prism ... pathologies and are recommended for ... etc.) and Rhegmatogenus retinal detachment. ... panretinal photocoagulation and other midperipheral ...
... High-Mag 1.5x is specifically designed ... in macular hole surgery, optic ... membrane removal, traditional macular edema ... magnification. This lens was developed ...
Medicine Products: